Cystic and Idiopathic Pulmonary Fibrosis: Risk Factors, Management and Long-Term Health Outcomes

Lorenzo Robertson (Editor)

Series: Pulmonary and Respiratory Diseases and Disorders
BISAC: MED079000



Volume 10

Issue 1

Volume 2

Volume 3

Special issue: Resilience in breaking the cycle of children’s environmental health disparities
Edited by I Leslie Rubin, Robert J Geller, Abby Mutic, Benjamin A Gitterman, Nathan Mutic, Wayne Garfinkel, Claire D Coles, Kurt Martinuzzi, and Joav Merrick


Digitally watermarked, DRM-free.
Immediate eBook download after purchase.

Product price
Additional options total:
Order total:



Cystic fibrosis (CF) is one of the most common autosomal recessive disorders in the Caucasian population with an estimated incidence of 1 in 2,500 childbirths. While this disease affects several organ systems of the body, morbidity and mortality is chiefly related to the extent of pulmonary involvement. Idiopathic pulmonary fibrosis (IPF) is the most common idiopathic interstitial disease of the lung of unknown etiology with a median survival time of about 3 years. IPF occurs mainly in men older than 60 years who have comorbidities such as pulmonary hypertension, COPD, lung cancer, gastro-esophageal reflux, ischemic heart disease and obstructive sleep apnoea. This book provides current research on risk factors of CF and IPF, as well as management options and long-term health outcomes of the disorders. (Imprint: Nova Biomedical)


Chapter 1. Clinical Manifestations of Cystic Fibrosis and Their Management
Ibrahim A. Janahi and Abdul Rehman (Professor of Clinical Pediatrics, Weill-Cornell Medical College–Qatar, and others)

Chapter 2. Liver Disease in Cystic Fibrosis: Prevalence, Risk Factors, and Outcomes
Fustik Stojka (Center for Cystic Fibrosis, University Children’s Clinic, Skopje, R. Macedonia)

Chapter 3. Lung Transplantation for Cystic Fibrosis
Zubin Mukadam, Mehgan Holland and Keith C. Meyer (Department of Medicine, University of Wisconsin School of Medicine and Public Health, Madison, WI, USA, and others)

Chapter 4. New Cystic Fibrosis Therapy
Sabrine Oueslati (Biochemistry Laboratory, Children’s Hospital; Research laboratory, “Haemoglobinopathies and Cystic fibrosis, LR00SP03”, Tunis, Tunisia)

Chapter 5. Distinct Patterns of Pulmonary Injury and Fibrosis Induced by Intratracheal and Subcutaneous Bleomycin in the Mouse: Relevance for Distinct Forms of Human Lung Fibrosis
Anna P. Lam, Erica L. Herzog, Denisa Melichian, Joseph Sennello, Ye Gan, Kirtee Raparia, Robert Homer, Anjana Yeldandi, and John Varga (Divisions of Rheumatology, Pulmonary and Critical Care Medicine and Department of Pathology, Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA, and others)

Chapter 6. Sleep Disorders in Idiopathic Pulmonary Fibrosis
Hans Schweisfurth (Institute for Pulmonary Research (IPR), Cottbus, Germany)

Chapter 7. N-acetylcysteine therapy in Idiopathic Pulmonary Fibrosis
E. Rindone, L. Rosset and C. Carnuccio (Division of respiratory disease, Department of Clinical Biological Sciences, Faculty of Medicine and Surgery, San Luigi Gonzaga, University of Turin, Turin, Italy, and others)


You have not viewed any product yet.